# Federal Register #2026-20705

Prospective Exclusive License for Antibodies and Related Compositions Targeting SFTS Virus

**Buyer:** National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS)
**Posted:** October 09, 2026
**Respond By:** October 26, 2026
**Identifier:** 2026-20705
**NAICS:** 533110

NIAID is considering a commercial license for intellectual property covering antibodies against Severe Fever with Thrombocytopenia Syndrome (SFTS) virus.
- Government buyer and licensing office: U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Technology Transfer and Intellectual Property Office.
- Proposed licensee: Korea National Institute of Health.
- License scope: Exclusive, sublicensable, royalty-bearing license of NIAID’s rights in jointly owned patent rights to support commercial development and marketing.
- Technology: Antibodies and antigen-binding fragments that bind SFTS virus envelope glycoproteins, including Gn- and Gc-targeting antibodies, plus related pharmaceutical and diagnostic compositions for prevention, diagnosis, mitigation, or treatment of SFTS infection.
- Patent reference: Korean Patent Application No. 10-2025-0196127; NIH Tracking Number E-102-2025-0.
- No products, product quantities, or separate services are being purchased; this is a prospective intellectual-property license notice.

### Description

The National Institute of Allergy and Infectious Diseases (NIAID) is contemplating an exclusive, sublicensable, royalty-bearing patent license to the Korea National Institute of Health. The license concerns patent rights for antibodies and antigen-binding fragments that bind Severe Fever with Thrombocytopenia Syndrome virus antigen, along with related pharmaceutical and diagnostic compositions for prevention, diagnosis, mitigation, or treatment of infection. The license is intended to consolidate jointly owned patent rights for commercial development and marketing. Written comments and license applications received by October 26, 2026, will be considered.

[View original listing](https://www.federalregister.gov/documents/2026/10/09/2026-20705/prospective-grant-of-exclusive-license-inter-institutional-agreement-institution-lead-antibody)